Progenics Pharma (PGNX) Misses Q3 EPS by 3c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.52, $0.03 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $53.9 million versus the consensus estimate of $52.9 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates